Use of positron emission tomography in anticancer drug development

被引：21
|
作者：
Aboagye, EO [1 ]
Price, PM [1 ]
机构：
[1] Hammersmith Hosp, Dept Canc Med, Fac Med, Imperial Coll Sci Technol & Med,PET Oncol Grp, London, England
来源：
INVESTIGATIONAL NEW DRUGS | 2003年 / 21卷 / 02期
关键词：
positron emission tomography; pharmacokinetics; pharmacodynamics; modeling; anticancer; drug development;
D O I：
10.1023/A:1023521412787
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[C-11]thymidine, [F-18]fluorodeoxyglucose, (H2O)-O-15, (CO)-O-15, and receptor ligands.
引用
收藏
页码：169 / 181
页数：13
相关论文
共 50 条
  • [1] Use of Positron Emission Tomography in Anticancer Drug Development
    Eric O. Aboagye
    Patricia M. Price
    [J]. Investigational New Drugs, 2003, 21 : 169 - 181
  • [2] Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
    Lamberts, Laetitia E.
    Williams, Simon P.
    van Scheltinga, Anton G. T. Terwisscha
    Lub-de Hooge, Marjolijn N.
    Schroeder, Carolien P.
    Gietema, Jourik A.
    Brouwers, Adrienne H.
    de Vries, Elisabeth G. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1491 - 1503
  • [3] Positron emission tomography imaging of small animals in anticancer drug development
    Aboagye, Eric O.
    [J]. MOLECULAR IMAGING AND BIOLOGY, 2005, 7 (01) : 53 - 58
  • [4] Positron Emission Tomography Imaging of Small Animals in Anticancer Drug Development
    Eric O. Aboagye
    [J]. Molecular Imaging and Biology, 2005, 7 : 53 - 58
  • [5] Positron emission tomography in drug development and drug evaluation
    Paans, AMJ
    Vaalburg, W
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (16) : 1583 - 1591
  • [6] Positron emission tomography in serotonergic drug development
    Andrée, B
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 2002, 68 (01) : 90 - 91
  • [7] Positron emission tomography: Applications in drug discovery and drug development
    Wang, JL
    Maurer, L
    [J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (11) : 1053 - 1075
  • [8] Positron emission tomography application to drug development and research
    Salvadori, Piero A.
    [J]. PHYSICS FOR MEDICAL IMAGING APPLICATIONS, 2007, 240 : 341 - 351
  • [9] Positron emission tomography molecular imaging for drug development
    Matthews, Paul M.
    Rabiner, Eugenii A.
    Passchier, Jan
    Gunn, Roger N.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 175 - 186
  • [10] The potential of positron-emission tomography to study anticancer-drug resistance
    West, CML
    Jones, T
    Price, P
    [J]. NATURE REVIEWS CANCER, 2004, 4 (06) : 457 - 469
12345